SZodixStudyAcademic Library
DashboardShelvesOpen accessMy libraryInboxNotesWriteLearnAlerts
More
Ask your libraryNotificationsQuick citeReview
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40
4 references·16 citing·39 second hop
Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40 (1998)Cost effectiveness analysis of improved b…Model of Complications of NIDDM: II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia (1997)Model of Complications of NID…ESTIMATING CONFIDENCE INTERVALS FOR COST-EFFECTIVENESS RATIOS: AN EXAMPLE FROM A RANDOMIZED TRIAL (1996)ESTIMATING CONFIDENCE INTERVA…Cost-Effectiveness in Health and Medicine (1996)Cost-Effectiveness in Health …Costs, effects and C/E‐ratios alongside a clinical trial (1994)Costs, effects and C/E‐ratios…Cost-effectiveness of Interventions to Manage Diabetes: Has the Evidence Changed Since 2008? (2020)Cost-effectiveness of Interve…Cost effectiveness of strategies to combat cardiovascular disease, diabetes, and tobacco use in sub-Saharan Africa and South East Asia: mathematical modelling study (2012)Cost effectiveness of strateg…Cost-Effectiveness of Intensified Versus Conventional Multifactorial Intervention in Type 2 Diabetes (2008)Cost-Effectiveness of Intensi…Using and interpreting cost-effectiveness acceptability curves: an example using data from a trial of management strategies for atrial fibrillation (2006)Using and interpreting cost-e…Need for differential discounting of costs and health effects in cost effectiveness analyses (2005)Need for differential discoun…Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72) (2005)Cost-utility analyses of inte…Screening for Type 2 Diabetes Mellitus: A Cost-Effectiveness Analysis (2004)Screening for Type 2 Diabetes…Assessing generalisability by location in trial‐based cost‐effectiveness analysis: the use of multilevel models (2004)Assessing generalisability by…The impact of diabetes‐related complications on healthcare costs: results from the United Kingdom Prospective Diabetes Study (UKPDS Study No. 65) (2003)The impact of diabetes‐relate…Advantages of Using the Net-Benefit Approach for Analysing Uncertainty in Economic Evaluation Studies (2003)Advantages of Using the Net-B…El coste de la diabetes tipo 2 en España. El estudio CODE-2 (2002)El coste de la diabetes tipo …The methodologic partnership of effectiveness reviews and cost-effectiveness analysis (2001)The methodologic partnership …An economic model of the long-term health care burden of Type II diabetes (2001)An economic model of the long…Direct medical costs for patients with type 2 diabetes in Sweden (2000)Direct medical costs for pati…Definition, interpretation and calculation of cost-effectiveness acceptability curves (2000)Definition, interpretation an…A Bayesian approach to stochastic cost-effectiveness analysis (1999)A Bayesian approach to stocha…Net Health Benefits (1998)Representing uncertainty: the role of cost‐effectiveness acceptability curves (2001)Using the net benefit regression framework to construct cost-effectiveness acceptability curves: an example using data from a trial of external loop recorders versus Holter monitoring for ambulatory monitoring of "community acquired" syncope (2006)Economic evaluation of a task-shifting intervention for common mental disorders in India (2012)Health economic evaluation: Important principles and methodology (2013)The Economics of Welfare (1933)Methods for the Economic Evaluation of Health Care Programmes (2005)Discounting and decision making in the economic evaluation of health-care technologies (2010)Handleiding voor kostenonderzoek: methoden en referentieprijzen voor economische evaluaties in de gezondheidszorg (2012)UPDATE OF THE DUTCH MANUAL FOR COSTING IN ECONOMIC EVALUATIONS (2012)Probabilistic Sensitivity Analysis Using Monte Carlo Simulation (1985)Lifetime Benefits and Costs of Intensive Therapy as Practiced in the Diabetes Control and Complications Trial (1996)Cost-effectiveness of Intensive Glycemic Control, Intensified Hypertension Control, and Serum Cholesterol Level Reduction for Type 2 Diabetes (2002)Cost-Effectiveness of Screening for Pre-Diabetes Among Overweight and Obese U.S. Adults (2007)Screening Adults for Pre-Diabetes and Diabetes May Be Cost-Saving (2010)A Guide to Simulation (1983)How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. (1992)Handling Uncertainty in Cost-Effectiveness Models (2000)Cost‐effectiveness acceptability curves – facts, fallacies and frequently asked questions (2004)Cost-Effectiveness Analysis Alongside Clinical Trials II—An ISPOR Good Research Practices Task Force Report (2015)Confidence intervals or surfaces? Uncertainty on the cost-effectiveness plane (1998)Analysis of uncertainty in health care cost-effectiveness studies: an introduction to statistical issues and methods (2002)Non‐parametric methods for cost‐effectiveness analysis: the central limit theorem and the bootstrap compared (2009)Pulling cost-effectiveness analysis up by its bootstraps: A non-parametric approach to confidence interval estimation (1997)BAYESIAN VALUE-OF-INFORMATION ANALYSIS (2001)Incremental cost-effectiveness ratios (ICERs): The silence of the lambda (2005)Regression models for analyzing costs and their determinants in health care: an introductory review (2011)Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40 (1998)Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41) (2000)Event Rates, Hospital Utilization, and Costs Associated with Major Complications of Diabetes: A Multicountry Comparative Analysis (2010)Diabetes expenditure, burden of disease and management in 5 EU countries (2012)The impact of diabetes‐related complications on healthcare costs: new results from the UKPDS (UKPDS 84) (2014)EQ-SD: a measure of health status from the EuroQol Group (2001)Innovation in the pharmaceutical industry: New estimates of R&D costs (2016)Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses (2016)Confidence Intervals for Cost-Effectiveness Ratios: A Comparison of Four Methods (1997)The Distribution of Health Care Costs and Their Statistical Analysis for Economic Evaluation (1998)Lifetime Costs of Complications Resulting From Type 2 Diabetes in the U.S. (2002)Health Care Economic Analyses and Value-Based Medicine (2003)
this work references cited by second hop

References

  • 1996Cost-Effectiveness in Health and Medicine7,192 cited
  • 1994Costs, effects and C/E‐ratios alongside a clinical trial963 cited
  • 1997Model of Complications of NIDDM: II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia333 cited
  • 1996ESTIMATING CONFIDENCE INTERVALS FOR COST-EFFECTIVENESS RATIOS: AN EXAMPLE FROM A RANDOMIZED TRIAL313 cited

Cited by

  • 2000Definition, interpretation and calculation of cost-effectiveness acceptability curves292 cited
  • 2006Using and interpreting cost-effectiveness acceptability curves: an example using data from a trial of management strategies for atrial fibrillation279 cited
  • 1999A Bayesian approach to stochastic cost-effectiveness analysis253 cited
  • 2003The impact of diabetes‐related complications on healthcare costs: results from the United Kingdom Prospective Diabetes Study (UKPDS Study No. 65)246 cited
  • 2005Need for differential discounting of costs and health effects in cost effectiveness analyses225 cited
  • 2004Screening for Type 2 Diabetes Mellitus: A Cost-Effectiveness Analysis178 cited
  • 2020Cost-effectiveness of Interventions to Manage Diabetes: Has the Evidence Changed Since 2008?164 cited
  • 2005Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72)155 cited
  • 2002El coste de la diabetes tipo 2 en España. El estudio CODE-2

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work

154 cited
  • 2000Direct medical costs for patients with type 2 diabetes in Sweden153 cited
  • 2001The methodologic partnership of effectiveness reviews and cost-effectiveness analysis150 cited
  • 2008Cost-Effectiveness of Intensified Versus Conventional Multifactorial Intervention in Type 2 Diabetes147 cited
  • 2003Advantages of Using the Net-Benefit Approach for Analysing Uncertainty in Economic Evaluation Studies124 cited
  • 2004Assessing generalisability by location in trial‐based cost‐effectiveness analysis: the use of multilevel models117 cited
  • 2001An economic model of the long-term health care burden of Type II diabetes115 cited
  • 2012Cost effectiveness of strategies to combat cardiovascular disease, diabetes, and tobacco use in sub-Saharan Africa and South East Asia: mathematical modelling study103 cited